Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Официальное название

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501

Обзор

This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.

Подробное описание

PRIMARY OBJECTIVE:

I. Determine how polyamine depletion impacts extracellular guanidinoacetate abundance.

SECONDARY OBJECTIVES:

I. Determine the impact of polyamine depletion on polyamine abundance and the global extracellular metabolome within live human gliomas, in situ.

II. Assess the feasibility of longitudinal microdialysis to evaluate pharmacodynamic responses of in situ gliomas to therapeutic intervention in a post-operative setting.

III. Assess the central nervous system (CNS) pharmacokinetics of DFMO and AMXT 1501.

IV. Adverse effects of study drugs in the immediate postoperative setting during microdialysis.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients undergo surgical resection with magnetic resonance imaging (MRI) and placement of catheters for microdialysis at baseline. Patients receive DFMO orally (PO) in combination with AMXT 1501 PO on days 1-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection as well as undergo computed tomography (CT) and collection of blood on study.

ARM II: Patients undergo surgical resection with MRI and placement of catheters for microdialysis at baseline. Patients receive DFMO PO and AMXT 1501 PO on days 3-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection, as well as undergo CT and collection of blood on study.

ARM III: Patients undergo surgical resection with MRI and placement of catheters for microdialysis at baseline. Patients receive DFMO PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection, as well as undergo CT and collection of blood on study.

Вмешательства

• Процедура Biospecimen Collection
  Undergo collection of blood
• Процедура Computed Tomography
  Undergo CT
• Препарат Eflornithine
  Given PO
• Процедура Magnetic Resonance Imaging
  Undergo MRI
• Препарат Polyamine Transport Inhibitor AMXT-1501 Dicaprate
  Given PO
• Процедура Resection
  Undergo surgical resection
• Устройство Microdialysis
  Undergo Microdialysis
• Процедура Placement
  Undergo placement of catheters

Первичные конечные точки

• Change in the tumor/brain extracellular guanidinoacetate ratio [Срок оценки: Baseline up to 2 months]

Вторичные конечные точки (6)

• Measured extracellular levels of glutamate in tumor and brain microdialysates [Срок оценки: Up to 2 months]
• Proportion of longitudinal microdialysis aliquots containing > 30 uL of microdialysate [Срок оценки: Up to post-operative day 5]
• Central nervous system free drug levels from microdialysate - DFMO [Срок оценки: Up to 2 months]
• Central nervous system free drug levels from microdialysate - AMXT 1501 [Срок оценки: Up to 2 months]
• AMXT 1501 brain/plasma ratio over time [Срок оценки: Up to 2 months]
• Incidence of adverse events [Срок оценки: Up to 2 months]

Критерии участия

Критерии включения

• Age >= 18 years
• Clinical and radiographic evidence suggesting a diagnosis of a diffuse high grade glioma (HGG), or a prior diagnosis of a diffuse glioma
• Planned subtotal resection or biopsy due to tumor location, size, or other clinical indication deemed appropriate by the surgeon
• Provide written informed consent for the current study and the Neuro-Oncology biorepository for archiving of cerebrospinal fluid (CSF) and blood samples collected on this protocol. Willing to remain in the hospital at Mayo Clinic (Rochester, MN) for three days added to their standard post-operative stay to undergo longitudinal microdialysis
• Absolute neutrophil count (ANC) >= 1.5 x 10\^9/L without transfusion within 7 days preceding the lab assessment (obtained =< 14 days prior to registration)
• Platelet >= 100 x 10\^9/L, without transfusion within 7 days preceding the lab assessment (obtained =< 14 days prior to registration)
• Hemoglobin >= 9 g/dL, without transfusion support within 7 days preceding the lab assessment (obtained =< 14 days prior to registration)
• Activated partial thromboplastin time or partial thromboplastin time (aPTT or PTT) =< 1.5 x upper limit of normal (ULN) (obtained =< 14 days prior to registration)
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (obtained =< 14 days prior to registration)
• Total serum bilirubin =< 1.5 x ULN (obtained =< 14 days prior to registration)
• The patient is clinically euthyroid \[Thyroid Stimulating Hormone (TSH)\]
• Serum creatinine =< 1.5 x ULN or creatinine clearance >= 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above 1.5 x ULN (obtained =< 14 days prior to registration)
• Negative serum or urine pregnancy test is required for female subjects of childbearing age < 14 days prior to registration

Критерии исключения

• Inappropriate surgical candidates due to current or past medical history or uncontrolled concurrent illness which limits safety of or compliance to study proceedings
• Vulnerable populations: pregnant or nursing women, prisoners, mentally handicapped
• Unable to swallow tablets or who are at risk for impaired absorption of oral medication. NOTE: This includes but not limited to, refractory vomiting, gastric resection/bypass, and duodenal/jejunal resection
• Known hypersensitivity or allergy to DFMO or AMXT 1501
• Contraindication to MRI or administration of gadolinium

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Двойное слепое

Основная цель

Фундаментальное исследование

Центры проведения

США · 1 центр

• Mayo Clinic in Rochester — Rochester

Идентификаторы

NCT: NCT05717153 · 22-005690 · NCI-2022-10375 · R37CA276851

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗